Kyntra Bio, Inc. received a final $4.0 million holdback payment from AstraZeneca Treasury Limited on June 2, 2026, completing the collection of all amounts owed under the February 20, 2025, share purchase agreement. This agreement involved the sale of the company's China operations to AstraZeneca for approximately $220 million, which included $85 million in enterprise value and $135 million in net cash. Kyntra Bio, Inc. is a biotechnology company.